Yuexiang Pharmaceutical: Publishes preclinical research results on long-acting hypotensive siRNA drugs, expected to bring new breakthroughs in the treatment of high blood pressure.

Recently, the subsidiary of YOKANG Pharma, Beijing YOKANG Biotech Co., Ltd., published a research paper entitled "Design, pharmacology, and toxicology of a novel chemically modified siRNA targeting hepatic angiotensinogen" in the internationally renowned SCI journal Molecular Therapy-Nucleic Acids in the field of nucleic acid drugs. The article reported on the pre-clinical development process of a novel liver-targeted siRNA candidate drug targeting hepatic angiotensinogen - through bioinformatics screening, chemical modification optimization, and combining liver-targeting ligands, several siRNAs with inhibitory activity, duration, and safety comparable or superior to previous ones were successfully developed. This therapy is expected to bring new breakthroughs in the treatment of hypertension.